Duramed and estrogens
FDA refuses generic firm's request for an indefinite extension of the June 15 deadline for replies to the agency's proposed withdrawal of all ANDAs for generic conjugated estrogens on June 12. Duramed had sought the extension in a June 4 petition in which it alleged that FDA's May 4 ad hoc subcommittee on conjugated estrogens meeting was prejudiced by several panel members with conflicts of interest.
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”